Combination therapy with an LSD1 inhibitor and anti‐PD1 antibody remodeled the tumor microenvironment, reversing the acquired resistance and prolonging the duration of response to anti‐PD1 therapy. This evidence concerns the gene KDM1A and neoplasm.